YOLT 302
Alternative Names: YOLT-302Latest Information Update: 16 Jan 2024
Price :
$50 *
At a glance
- Originator YolTech Therapeutics
- Class Anti-infectives; Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Infections
Most Recent Events
- 25 Oct 2023 Early research in Infections in China (Parenteral), prior to October 2023 (YolTech Therapeutics pipeline, October 2023)
- 01 Jun 2022 YolTech Therapeutics files for patent protection for YOLT 302 (YolTech Therapeutics pipeline, October 2023)